Document:

3SBio, Inc.: Exhibit 4.17 - Filed by newsfilecorp.com

Exhibit 4.17 

Shenyang Sunshine Pharmaceutical Company Limited (hereinafter referred to as “Shenyang Sunshine”) 

Company Address/Legal Address: No. 3 A1, Road 10, Shenyang Economy & Technology Development Zone 

Dan Lou: Legal Representative of Shenyang Sunshine 

Identity Card No: xxxxxx 

Supplementary Agreement for Purchase Agreement for Acquisition of Equity Interest 

Mr. Lou Dan is the shareholder of Liaoning Sunshine Pharmaceutical Company Limited (hereinafter “Liaoning Sunshine”) and holds 100% equity of Liaoning Sunshine. Shenyang Sunshine, Mr. Lou Dan, and Liaoning Sunshine signed a series of
relevant agreements for business cooperation and for specifying equity relationship (“previous relevant agreements”) in 2006 and 2007. 

Now, Mr. Lou Dan and Shenyang Sunshine hope to make further clarifications and descriptions with regard to the following matters and signed the following agreement in Shenyang on February 3, 2010: 1. Shenyang Sunshine is entitled to appoint the
management of Liaoning Sunshine, including the general manager, financial director and other managers. 

2. Shenyang Sunshine agrees to provide financial support for Liaoning Sunshine if necessary, including but not limited to bearing the operation losses of Liaoning Sunshine. Meanwhile, Shenyang Sunshine does not require Liaoning Sunshine to give
return for its loss bearing. 

3. Shenyang Sunshine is entitled to unilaterally modify the proportion of payment from Liaoning Sunshine to Shenyang Sunshine regulated in the business cooperation agreement with Liaoning Sunshine (signed on January 1, 2007); 4. If Liaoning Sunshine
has to undergo the dissolution or transfer liquidation (“compulsory liquidation”) pursuant to the requirements of Chinese laws, Liaoning Sunshine shall sell all its assets at the minimum prices permitted in the Chinese laws to Shenyang
Sunshine or the other third party licensed by Shenyang Sunshine. The sales prices are paid by the investment funds for equity of Liaoning Sunshine (the investment funds are the payment in advance made by Shenyang Sunshine to Mr. Lou Dan); 5. After
the compulsory liquidation mentioned in the above 4, as the original shareholder of Liaoning Sunshine, Mr. Lou Dan shall return the excessive part (the payment in advance made by Shenyang Sunshine to Mr. Lou Dan is higher than the sales prices of
Liaoning Sunshine) to Shenyang Sunshine. If the direct return is not permitted by Chinese laws, Mr. Lou Dan shall return the same based on the modes permitted in Chinese laws. 

6. The equity distribution (if any) related to Liaoning Sunshine made to Mr. Lou Dan in any form during any period shall be returned to Shenyang Sunshine in the form permitted by laws. 

7. Any modification or change of previous relevant agreements shall be approved by Shenyang Sunshine in advance. 

8. This Agreement came into effect from January 1, 2009. 

Exhibit 4.17 

If this Agreement is in conflict with the previous relevant
agreements, this Agreement shall prevail.3SBio, Inc.: Exhibit 4.18 - Filed by newsfilecorp.com

Exhibit 4.18 

 

 

Supplementary Agreement for Purchase Agreement for Acquisition of 

Equity Interest 

In 

Liaoning Sunshine Bio-Pharmaceutical Company Limited 

Between 

Shenyang Sunshine Pharmaceutical Company Limited

 And 

Dan Lou 

 

 

Exhibit 4.18 

SUPPLEMENTARY AGREEMENT FOR PURCHASE AGREEMENT FOR ACQUISITION OF EQUITY INTEREST 

THIS SUPPLEMENTARY AGREEMENT was entered into between the following parties in Shenyang City, Liaoning Province on February 3, 2010: 

Party A: Shenyang Sunshine Pharmaceutical Company Limited 

Legal Address: No. 3 A1, Road 10, Shenyang Economy & Technology Development Zone 

Legal Representative: Dan Lou 

Party B: Dan Lou 

Identity Card Number: xxxxxx 

WHEREAS, 

1. Party A is a foreign invested wholly owned enterprise established and validly subsisted according to the laws of the People’s Republic of China (hereinafter the “PRC”), and signed the Equity Acquisition Agreement with
regard to the acquisition of 100% equity (hereinafter referred to as “Subject Equity”) of Liaoning Sunshine Pharmaceutical Company Limited (hereinafter “Liaoning Sunshine”) with Party B on December 1, 2006; 2. Party B is a
legitimate Chinese citizen and holds 100% equity of Liaoning Sunshine; 3. Liaoning Sunshine is a company with limited liability incorporated and validly subsisted according to the laws of the PRC, the business scope of which covers the sale of
bio-products (including bio-pharmaceuticals), biochemical medicines, chemical preparations, antibiotics, prepared traditional Chinese medicines (efficacious before December 31, 2009) and diagnostic medicines; the sale of three types of medical
equipment (excluding the disposable sterile medical equipment) (efficacious before December 31, 2009); the manufacture, sale of special nutrition food; the self-operation and agency of various commodities and technologies and their export and import
(excluding those under restricted operation or prohibited to import and export by the State). Its registered capital is RMB 15 million. Party B and paid up in full; With regard to the acquisition of Subject Equity, Party A and Party B hereto reach
the following Supplementary agreement: Article 1 Both parties agree that the price to purchase the Subject Equity is RMB13.5 million. Article 2 Both parties confirm that, as of the date of signing this Supplementary agreement, Party A
has made payment for Subject Equity to Party B in full, and Party A does not have to perform any payment obligation with regard to the purchase of Subject Equity to Party B at any time any more. Article 3 Party B shall, pursuant to the
agreement in the Equity Acquisition Agreement, make coordination in the completion of registration matters of industrial & commercial change of Subject Equity after being permitted by the laws, and shall not claim any payment obligation
with regard to the transfer of Subject Equity to Party A any more. 

Article 4 This Supplementary Agreement came into effect from January 1, 2009. 

Article 5 Both parties agree that, after signing this Supplementary Agreement, any open terms of
this Supplementary Agreement is subject to further negotiation and a supplementary agreement. Such supplementary agreement shall form an integral part of the Equity Acquisition Agreement and this Supplementary Agreement. 

Exhibit 4.18 

Article 6 Either party breaching any representations, warranties and commitments or any clauses in this Supplementary Agreement shall constitute a default. The defaulting party shall compensate the non-defaulting party fully and adequately.

Article 7 Any dispute over this Supplementary Agreement arisen in the performance of the same shall be settled by the Parties hereto through friendly consultation. In case the dispute cannot be settled through consultation, either party may
sue at a court in the PRC with competent jurisdiction against the other party. 

Article 8 The execution, validity, interpretation, performance of this Supplementary Agreement, and the settlement of disputes hereof, all are governed by the laws of the PRC. 

Article 9 Without the written consent of the other party, either party shall not transfer its rights under this Supplementary Agreement. This Supplementary Agreement shall be binding on the successors and approved transferees of both parties.

Article 10 If this Supplementary Agreement is inconsistent with the Equity Acquisition Agreement, this Supplementary Agreement shall prevail, and other contents of the Equity Acquisition Agreement remain unchanged. 

Article 11 This Supplementary Agreement is made in duplicate, with Party A and Party B each retaining one copy thereof, respectively. Each original shall be of the same legal validity. 

IN WITNESS WHEREOF, the Parties hereof hereby formally authorize their respective representatives to sign this Supplementary Agreement as of the date and in the place first above written.

Exhibit 4.183SBio, Inc.: Exhibit 4.19 - Filed by newsfilecorp.com

Exhibit 4.19 

AMENDMENT TO PURCHASE AGREEMENT FOR ACQUISITION OF EQUITY INTEREST 

   Amendment No. 1 dated as of December 31, 2012 (this “Amendment”) to the PURCHASE AGREEMENT FOR ACQUISITION OF EQUITY INTEREST, entered into  on December 1, 2006 (the “Agreement”), as
supplemented, between Shenyang Sunshine Pharmaceutical Company Limited, a PRC company (the “Company” or “Party A”)), and Mr. Dan LOU (the “Nominee” or “Party B”)).  

     WHEREAS, the Company and the Nominee are parties to the Agreement; 

     NOW, THEREFORE, in consideration of the promises and mutual agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Company
and the Nominee hereby agree as follows: 

     A. Amendment.  

(i) Article 1 of the Agreement is hereby amended and restated in its entirety, to read as follows:  “Party B hereby agrees to transfer, irrevocably, to Party A the Subject Equity at the price as determined under Article 2 hereof and
change the title of the Subject Equity under the name of Party A upon the satisfaction of the following condition precedent: the relevant PRC government approval, if any, has been obtained to permit Party A’s holding the Subject
Equity.” 

(ii) A new Article 6A shall be added after Article 6 and before Article 7 as follows: 

“Without the approval of Party A, Party B shall cause Liaoning Sunshine not to enter into any major contracts involving value over RMB100,000 except in the ordinary course of business.”  

(iii) Article 13 of the Agreement is hereby amended and restated in its entirety,  to read as follows: 

"(1) Party A may unilaterally revoke or terminate the agreement with prior notice to but not consent of Party B. (2) Party B may not revoke or terminate the Agreement. (3) Any amendment or modification to this Agreement, to be valid, shall be in
writing and signed by all parties hereto. Party A has sole discretion to amend or supplement this Agreement whilst Party B shall cooperate to sign such amendments or supplement coming into force. ” 

Exhibit 4.19 

For avoidance of doubt, (x) this Agreement shall continue and be in full force indefinitely, other than provided in the foregoing or in Article 7; and (y) in each instance of termination or revocation by Party A, Party B shall refund Party A all
payments made hereunder by Party A. 

(iv) Article 16 of the Agreement is hereby amended and restated in its entirety to read as follows:  "(1) Party A may transfer the rights and obligations hereunder, in whole or in part, to any third party person or persons as designated in
absolute discretion by Party A.  (2) Without the written consent of Party A, Party B shall not transfer its rights and obligations hereunder, in whole or in part. (3) This Agreement shall be binding on the successors and approved transferees of both
parties." 

     B. Effect of Amendment. Except as expressly set forth herein, the Agreement shall not by implication or otherwise be supplemented or amended by virtue of this Amendment, but shall remain in full force and effect, as amended hereby. This
Amendment shall be construed in accordance with and as a part of the Agreement, and all terms, conditions, representations, warranties, covenants and agreements set forth in the Agreement and each other instrument or agreement referred to therein,
except as herein amended, are hereby ratified and confirmed. To the extent that there is a conflict between the terms and provisions of the Agreement and this Amendment, the terms and provisions of this Amendment shall govern for purposes of the
subject matter of this Amendment only. This Amendment is in English language, which, together with the English translation of the Agreement as filed with the U.S. Securities and Exchange Commission on January 19, 2007 on Form F-1, shall be the
official version for all purposes. 

     C. Severability. If any provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or other authority to be invalid, illegal or unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Amendment shall remain in full force and effect and shall in no way be effected, impaired or invalidated. 

     D. Governing Law. This Amendment shall be deemed to be a contract made under the laws of the People's Republic of China. and for all purposes shall be governed by and construed in accordance with such laws. 

     F. Counterparts. This Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same
instrument. 

     G. Descriptive Headings. Descriptive headings appear herein for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof. 

     H. Effective Date of Amendment. This Amendment shall be deemed effective as December 31, 2012, as if executed on such date. 

[Signature Page Follows on the Next Page] 

Exhibit 4.19 

PARTY A: SHENYANG SUNSHINE 

PHARMACEUTICAL COMPANY LIMITED 

By: /s/ Jing  Lou 

Name: Jing Lou 

Title: Chairman 

PARTY B: Mr. Dan LOU  

By:  /s/ Dan Lou 

Name: Dan Lou

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]